An advanced Ad5 vector gene delivery platform with deletions of E1, E2b, and E3 gene regions, known as Ad5 [E1-, E2b-], was constructed as a cancer vaccine regardless of the existence of pre-existing Ad5 immunity (Gabitzsch et al., 2015). This evidence concerns the gene PSEN2 and cancer.